Public comment period · §3
Draft monograph: Hexarelin — disposition
The disposition of every submission and the amendments that resulted.
§3Disposition and amendments
§3.1Disposition table
Table 1. Every submission with its disposition. Each row links to the submission in full.
| Reference | Respondent | Point raised | Disposition |
|---|---|---|---|
| DRAFT-HEXARELIN-MO/001 | Dr Hyacinth Drakeford-Amadi | The interaction section lists mechanisms rather than interactions | Accepted in part |
| DRAFT-HEXARELIN-MO/002 | Dr Theodora Ingelbrecht | Evidence for one member of the class is presented as evidence for this compound | Accepted |
| DRAFT-HEXARELIN-MO/003 | Dr Fitzwilliam Danquah-Öberg | A purity figure from a certificate is quoted as though it were a content figure | Accepted |
| DRAFT-HEXARELIN-MO/004 | Dr Vittoria Quintanilha | Trials are described as terminated where they completed as planned | Accepted in part |
| DRAFT-HEXARELIN-MO/005 | Ivo Mountstephen | The search date is not on the face of the document | Accepted |
| DRAFT-HEXARELIN-MO/006 | Dr Xenia Nyquist-Obiora | Guidance on lyophilised storage is missing | Noted, no amendment |
| DRAFT-HEXARELIN-MO/007 | Dr Henrike Jastrzębska | The pharmacokinetic section does not connect half-life to the dosing schedule | Accepted |
| 7 submissions in total. | |||
§3.2Summary by disposition
Table 2. Counts by disposition, with the meaning of each.
| Disposition | Count | Meaning |
|---|---|---|
| Accepted | 4 | The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission. |
| Accepted in part | 2 | Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined. |
| Noted, no amendment | 1 | The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response. |
| Not accepted | 0 | The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it. |
§3.3Resulting amendments
- The interaction section lists mechanisms rather than interactions — arising from DRAFT-HEXARELIN-MO/001. The interaction section is now divided into interactions reported in clinical use and interactions predicted from mechanism, with the second labelled as prediction. Where neither exists the section says so in one line rather than being padded.
- Evidence for one member of the class is presented as evidence for this compound — arising from DRAFT-HEXARELIN-MO/002. Class-level inferences are now labelled at the point of use, are excluded from the certainty rating for the compound, and are reported in a separate subsection stating which compound the underlying evidence concerns.
- A purity figure from a certificate is quoted as though it were a content figure — arising from DRAFT-HEXARELIN-MO/003. Purity and content are now reported in separate rows with separate definitions, and the monograph states that a purity figure sets no bound on content and that a content figure requires a determination against a standard of assigned content.
- Trials are described as terminated where they completed as planned — arising from DRAFT-HEXARELIN-MO/004. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
- The search date is not on the face of the document — arising from DRAFT-HEXARELIN-MO/005. The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.
- The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-HEXARELIN-MO/007. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-CP-055/3 · https://compoundevidence.com/comment-periods/draft-hexarelin-monograph/disposition/ · retrieved 30 July 2026